Pharma & Biotech — 2026年9月28日 週次レポート
Pharma & Biotechのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The week's defining tension is between a productive FDA approval environment and deepening uncertainty about the agency's leadership and independence. Multiple approvals landed — Lilly's weekly insulin, Merck's renal cell carcinoma combination, Grail's cancer blood test advisory endorsement — while the FDA commissioner nominee's evasive Senate testimony left unresolved questions about whether the agency will maintain scientific independence under political pressure. Industry faces a paradox: the…
- •Two simultaneous Phase 3 cardiovascular failures — Novartis's pelacarsen and Novo Nordisk's ziltivekimab — both hitting biological targets while failing to move clinical outcomes, constitute a significant inflection point for precision cardiology. The field has now accumulated enough high-profile biomarker-positive, outcome-negative failures to force a methodological reckoning about whether surrogate endpoints are reliable guides for cardiovascular drug development. This will reshape how compani…
- •The competitive landscape is consolidating around immunology and autoimmune disease as the next major battleground. Gilead's public commitment to I&I as a core pillar, J&J's TREMFYA axial PsA win, Kyverna's CAR-T autoimmune data, and multiple VC-backed startups entering the space signal that the field is transitioning from a niche to a primary arena — with implications for pricing, clinical trial competition, and regulatory review capacity.
- •Merck's extraordinary week — four regulatory milestones across three geographies and two new indications — contrasts sharply with Novo Nordisk's dual cardiovascular failure and strategic pivot, and Merck's own voluntary BLA withdrawal for ifinatamab deruxtecan. Even the strongest pipelines are uneven, and the week illustrates that regulatory success and pipeline setbacks can coexist within the same company in the same week.
- •The pandemic preparedness governance debate is intensifying at the UN level, with IFPMA escalating its engagement from IGWG 8 to the full UN High-Level Meeting. The industry's warning that certain WHO Pandemic Agreement proposals risk adding complexity to outbreak response reflects a fundamental tension between equitable access goals and the commercial incentives needed to sustain R&D investment in pandemic-relevant products — a tension that will shape the final agreement's terms.
今回の要点（13件）
- 1.Merck secured four regulatory milestones in a single week: FDA approval for WELIREG plus LENVIMA in renal cell carcinoma, FDA label update for WINREVAIR in PAH, Japanese approval for KEYTRUDA QLEX subcutaneous formulation, and positive Phase 2b/3 data for remigromig in diabetic macular edema [2].
- 2.Novartis's pelacarsen (Lp(a) HORIZON) and Novo Nordisk's ziltivekimab (ZEUS) both failed to reduce cardiovascular events despite hitting their biological targets, raising fundamental questions about biomarker surrogacy in cardiovascular drug development [1a].
- 3.FDA commissioner nominee Heidi Overton largely avoided direct answers on vaccines, abortion, and political independence during her Senate confirmation hearing [1b].
- 4.J&J announced CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients, and TREMFYA became the first IL-23 inhibitor to show MRI-confirmed axial inflammation reduction in psoriatic arthritis [7].
- 5.Gilead's CFO publicly described inflammation and immunology as the company's third core strategic pillar alongside virology and oncology [1c].
- 6.Eli Lilly's once-weekly insulin shot received FDA approval, setting up a direct rivalry with Novo Nordisk in the insulin market [1b].
- 7.An FDA advisory panel endorsed Grail's blood test for cancer detection, saying benefits outweigh risks [1].
- 8.HHS unveiled new initiatives to reduce animal testing in drug development on 2026-09-22 [1], paralleling EMA's earlier NAMs pilot program.
- 9.The White House plan to increase control of NIH grants appears 'dead' per STAT News on 2026-09-23 [1], reducing near-term risk to research funding independence.
- 10.IFPMA submitted statements at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response on 2026-09-25 and 2026-09-26, warning that some WHO Pandemic Agreement proposals risk adding complexity to outbreak response [12].
- 11.Novo Nordisk outlined a new strategy focused on obesity and direct-to-consumer work, signaling a commercial pivot following recent clinical setbacks [1].
- 12.Merck voluntarily withdrew the BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer on 2026-09-25 [2].
- 13.Drugmakers and biotech VCs showed reinvigorated interest in osteoporosis treatments, driven by new FDA guidance and frustration with existing therapies [11].
市場動向
FDA Approval Cadence Accelerates Across Multiple Therapeutic Areas
Building on the prior week's Sanfilippo gene therapy approval, the FDA this week approved Eli Lilly's once-weekly insulin shot, Merck's WELIREG plus LENVIMA combination for advanced renal cell carcinoma, and an FDA advisory panel endorsed Grail's blood test for cancer detection — all within the same reporting period [1b] [2]. This multi-indication approval surge signals that the FDA, despite staffing constraints, is maintaining a high-throughput approval environment across oncology, rare disease…
Cardiovascular Precision Medicine Faces a Reckoning After Phase 3 Failures
Two highly anticipated Phase 3 cardiovascular trials failed to translate biomarker success into clinical outcomes this period. Novartis's pelacarsen (Lp(a) HORIZON trial) successfully lowered lipoprotein(a) levels but did not reduce cardiovascular events, and Novo Nordisk's ziltivekimab (ZEUS trial) hit its biological target without improving clinical outcomes [1a]. These back-to-back failures raise fundamental questions about whether biomarker reduction alone is a sufficient surrogate for cardi…
Osteoporosis Emerges as a Reinvigorated Investment Frontier
A long-awaited regulatory shift by the FDA has reignited pharmaceutical and venture capital interest in osteoporosis treatments. According to STAT News, Eli Lilly is recruiting scientists for osteoporosis research, and venture capitalists are making bone health a priority — despite the field having been largely abandoned due to safety concerns and cumbersome drug requirements [11]. The convergence of new FDA guidance and frustration with existing therapies is opening a market where many eligible…
Drug Pricing Restructuring Deepens Through Political and Legal Channels
The Trump administration's drug pricing agenda advanced on multiple fronts this week: STAT News reported that Trump's boast on drug pricing policy overstated state-level interest in the federal program [1], while an Indonesian court ruling against patent evergreening by the pharma industry was flagged as sending a critical message to patient advocates [1]. Separately, a jury awarded Nektar $90 million in damages against Eli Lilly for breach of contract in a drug co-development agreement [1b]. Th…
Immunology and Autoimmune Disease Become the Next Major Battleground
Multiple companies this week signaled aggressive moves into inflammation and immunology. Gilead's CFO described I&I as the third core pillar of the company's strategy alongside virology and oncology [1c]. Kyverna's CAR-T cell therapy showed lasting autoimmune benefit in long-term data [1d], and J&J announced TREMFYA met primary and major secondary endpoints in axial psoriatic arthritis [7]. The simultaneous strategic pivots by multiple large companies into I&I indicate the field is transitioning…
競合動向
Merck Delivers Multiple Regulatory Wins Across Geographies and Indications
Merck had an exceptionally active week: the FDA approved WELIREG (belzutifan) plus LENVIMA (lenvatinib) for certain previously treated adult patients with advanced renal cell carcinoma on 2026-09-25 [2] (company announcement — may reflect promotional framing); the FDA approved an update to WINREVAIR's label to include Phase 3 HYPERION trial data for recently diagnosed PAH patients on 2026-09-22 [2]; KEYTRUDA QLEX received Japanese approval for subcutaneous administration on 2026-09-21 [2]; and M…
Johnson & Johnson Advances Multiple Myeloma and Immunology Portfolios Simultaneously
J&J announced on 2026-09-25 that a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients in early-line relapsed/refractory multiple myeloma [7] (company announcement — may reflect promotional framing). A separate J&J release on 2026-09-25 reported TREMFYA is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in axial psoriatic arthritis, using objective MRI assessments [7]. J&J's simultaneous data readouts across…
Novo Nordisk Pivots Strategy Toward Obesity Diversification and Direct-to-Consumer
STAT News reported on 2026-09-21 that Novo outlined plans for obesity and direct-to-consumer work as part of a new strategy [1]. This strategic pivot follows the ZEUS cardiovascular trial failure and the prior week's rebrand, suggesting Novo is doubling down on its obesity franchise while seeking new commercial channels. Endpoints News also noted Novo is pursuing bolt-on deals to diversify its pipeline [6], indicating the company is simultaneously pursuing internal and external pipeline renewal.
Gilead Signals Immunology as Core Third Pillar Alongside Virology and Oncology
Gilead's CFO Andy Dickinson told investors at the Cantor Global Healthcare Conference that inflammation and immunology is one of the three scientific areas that are the company's core focus, describing it as 'the third leg of the stool' alongside virology and oncology [1c]. This public commitment to I&I as a strategic pillar — not merely a pipeline addition — signals a long-term competitive repositioning that will intensify competition with established I&I leaders like AbbVie and J&J.
Merck Voluntarily Withdraws Ifinatamab Deruxtecan BLA for Small Cell Lung Cancer
Merck announced on 2026-09-25 the voluntary withdrawal of the Biologics License Application for ifinatamab deruxtecan for certain patients with previously treated extensive-stage small cell lung cancer [2] (company announcement — may reflect promotional framing). This withdrawal, coming in the same week as multiple other Merck regulatory successes, highlights the uneven nature of even the strongest pipelines and signals that the small cell lung cancer indication remains a challenging regulatory …
制度・規制動向
FDA Commissioner Nomination Advances Amid Institutional Uncertainty
Trump's FDA commissioner nominee Heidi Overton faced a Senate confirmation hearing this week, where she largely avoided declaring her stance on vaccines, abortion, and whether she would resist political pressure from President Trump or RFK Jr., repeatedly pointing to existing law and agency policy [1b]. Former FDA commissioners published an opinion piece stating Overton has an opportunity to strengthen the FDA [1]. The Senate Finance Committee separately backed Chris Klomp, advancing him to a fu…
HHS Launches Animal Testing Reduction Initiatives in Drug Development
STAT News reported on 2026-09-22 that HHS unveiled new initiatives to reduce animal testing in drug development [1]. This aligns with the EMA's voluntary data submission pilot for New Approach Methodologies (NAMs) announced earlier in September, which allows developers to submit NAMs data and receive tailored feedback [3]. The parallel US and EU moves toward reducing animal testing signal a coordinated regulatory shift toward alternative testing methodologies that will reshape preclinical develo…
IFPMA Engages UN High-Level Meeting on Pandemic Preparedness with Industry Commitments
IFPMA submitted statements at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response on 2026-09-25 and 2026-09-26, urging governments to adopt policies enabling discovery and development of life-saving products and strengthen delivery systems [12] (company announcement — may reflect promotional framing). IFPMA warned that some proposals under the WHO Pandemic Agreement could add complexity and cost to future outbreak response and delay access to critical samples [9a]. This …
White House NIH Grant Control Plan Collapses; Congressional Oversight Intensifies
STAT News reported on 2026-09-23 that the White House plan to increase control of NIH grants appears 'dead' [1], while members of Congress pushed back on a plan to create a commission of political appointees to review NIH grants on 2026-09-21 [1]. This reversal of a major proposed change to NIH governance reduces near-term risk to the research funding environment, though the underlying political pressure on NIH independence remains.
PMDA Updates MID-NET Real-World Data Utilization and Foreign Manufacturer Registration
Japan's PMDA updated MID-NET utilization status and expert committee information on 2026-09-24, and published foreign manufacturer certification and registration numbers on the same date [4]. PMDA also published defect report information for medical devices, combination products, and regenerative medicine products for May 2026 on 2026-09-25 [4]. These updates reflect PMDA's ongoing expansion of real-world data infrastructure and international manufacturing oversight.
ソース活動
先週からの変化
Merck Achieves Four Regulatory Milestones in a Single Week
Merck secured FDA approval for WELIREG plus LENVIMA in renal cell carcinoma (2026-09-25), FDA label update for WINREVAIR in PAH (2026-09-22), Japanese approval for KEYTRUDA QLEX subcutaneous formulation (2026-09-21), and positive Phase 2b/3 data for remigromig in diabetic macular edema (2026-09-24) [2] (company announcement — may reflect promotional framing). This multi-front regulatory success in a single week is unprecedented in the current reporting period.
Cardiovascular Precision Medicine Suffers Dual Phase 3 Failures
Novartis's pelacarsen (Lp(a) HORIZON) and Novo Nordisk's ziltivekimab (ZEUS) both failed to reduce cardiovascular events despite hitting their biological targets, as reported by STAT News on 2026-09-24 [1a]. These back-to-back failures challenge the biomarker-as-surrogate paradigm in cardiovascular drug development and represent a significant setback for precision cardiology.
FDA Commissioner Nomination Hearing Advances Amid Evasive Testimony
FDA commissioner nominee Heidi Overton faced Senate confirmation questioning on vaccines, abortion, and political independence, largely avoiding direct answers per STAT News on 2026-09-24 and 2026-09-25 [1]. The Senate Finance Committee advanced Chris Klomp to a full Senate vote on 2026-09-24 [1]. FDA leadership transition is now in active motion, creating regulatory uncertainty for industry.
J&J Reports Five-Year CARVYKTI Remission Data and TREMFYA Axial PsA Win
J&J announced on 2026-09-25 that CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients, and that TREMFYA is the first IL-23 inhibitor to show significant improvement in spinal pain and stiffness in axial psoriatic arthritis using MRI-confirmed assessments [7] (company announcement — may reflect promotional framing). These data packages strengthen J&J's competitive position in both hematology and immunology.
IFPMA Escalates Pandemic Preparedness Engagement at UN High-Level Meeting
IFPMA submitted statements at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response on 2026-09-25 and 2026-09-26, escalating from its prior IGWG 8 statement on 2026-09-14 [12] (company announcement — may reflect promotional framing). IFPMA warned that certain WHO Pandemic Agreement proposals risk adding complexity and cost to future outbreak response.
示唆・見るべき論点（8件）
- 1.The dual cardiovascular Phase 3 failures of pelacarsen and ziltivekimab — both hitting biological targets while missing clinical outcomes — suggest that the cardiovascular field may be systematically overestimating the clinical relevance of novel biomarkers. Companies with cardiovascular programs built on biomarker surrogacy should urgently reassess their endpoint strategies before committing to Phase 3 investment.
- 2.Gilead's public declaration of I&I as a core strategic pillar [1c] will intensify competition for I&I assets, talent, and clinical trial sites. Companies already in the I&I space should expect higher deal valuations and more competitive licensing environments as Gilead deploys capital to build its third pillar.
- 3.The FDA commissioner nominee's evasive testimony on political independence [1b] creates a monitoring imperative for industry: companies with pending submissions should track whether post-confirmation FDA decision-making shows any deviation from established scientific standards, particularly in politically sensitive areas like vaccines and reproductive health.
- 4.J&J's five-year CARVYKTI remission data showing 50% of patients in treatment-free remission [7] is a landmark result that will accelerate the shift toward earlier CAR-T use in multiple myeloma. Competitors in the CAR-T space should expect J&J to use this data aggressively in label expansion and payer negotiations.
- 5.The osteoporosis market revival [11] driven by new FDA guidance represents a classic regulatory-unlocked opportunity: a large unmet need, established patient population, and prior industry abandonment due to regulatory barriers. First movers who can navigate the new guidance framework will have a significant advantage in a market where many eligible patients currently receive no treatment.
- 6.Merck's voluntary withdrawal of the ifinatamab deruxtecan BLA [2] in the same week as four other regulatory successes illustrates that even the most productive pipelines require active portfolio management. The withdrawal likely reflects a strategic decision to resubmit with stronger data rather than risk a formal rejection — a pattern that other companies with borderline datasets should consider.
- 7.The collapse of the White House NIH grant control plan [1] reduces near-term risk to academic research funding, but the underlying political pressure on NIH independence has not disappeared. Companies that rely on NIH-funded basic research as a pipeline feeder should monitor whether alternative mechanisms to influence grant allocation emerge.
- 8.IFPMA's escalation from IGWG 8 to the UN High-Level Meeting [12] signals that the industry views the current WHO Pandemic Agreement negotiations as a critical juncture. Companies with pandemic-relevant portfolios should engage with IFPMA's advocacy positions to ensure their commercial interests are represented in the final agreement framework.
信頼度サマリー
今週引用したソース 12 件あなたが選んだ 14 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
STAT News reporting from 2026-09-20 through 2026-09-27 covering FDA approvals for Lilly weekly insulin and Merck renal cell carcinoma combination, Grail cancer blood test advisory panel endorsement, Heidi Overton FDA commissioner nomination hearing, cardiovascular Phase 3 failures for pelacarsen and ziltivekimab, Novo Nordisk new obesity strategy, osteoporosis VC reinvigoration, HHS animal testing reduction initiatives, NIH grant control plan collapse, and Gilead immunology strategic pivot.
Merck press releases from 2026-09-21 through 2026-09-26 covering KEYTRUDA QLEX Japanese approval (2026-09-21), WINREVAIR label update for PAH (2026-09-22), remigromig BRUNELLO study primary endpoint met (2026-09-24), WELIREG plus LENVIMA FDA approval for renal cell carcinoma (2026-09-25), and ifinatamab deruxtecan BLA voluntary withdrawal (2026-09-25) (company announcements — may reflect promotional framing).
EMA news from 2026-09-23 through 2026-09-24 showing stable content from the prior period, with the most recent new items being the sodium oxybate benefit-risk review and ipidacrine review conclusions from 2026-09-18, and the CHMP meeting highlights from 14–17 September 2026.
PMDA updates from 2026-09-24 through 2026-09-26 covering MID-NET real-world data utilization updates (2026-09-24), foreign manufacturer certification registration (2026-09-24), defect report information for medical devices and regenerative medicine products for May 2026 (2026-09-25), and 2026 Master File seminar announcement (2026-09-25).
EFPIA updates from 2026-09-21 through 2026-09-25 including a new study published 2026-09-25 linking overweight and obesity to 278,000 deaths and the loss of 8 million years of healthy life in 8 European countries, and the ongoing EFPIA Statement on the Cloud and AI Development Act from 2026-09-18.
Endpoints News reporting from 2026-09-20 through 2026-09-27 covering Novo Nordisk pipeline diversification strategy, Lilly FDA approval for once-weekly insulin, Merck WELIREG kidney cancer approval, AbbVie Parkinson's dopamine therapy FDA approval, Mirum ultra-rare soft tissue disease approval, Kyverna CAR-T autoimmune long-term data, Grail cancer test advisory panel vote, and multiple biotech IPO and financing developments.
J&J press releases from 2026-09-21 through 2026-09-25 covering CAPLYTA Phase 3 bipolar mania study results (2026-09-21), TECVAYLI plus DARZALEX FASPRO model-based survival analysis (2026-09-23), CARVYKTI five-year treatment-free remission data in early-line multiple myeloma (2026-09-25), and TREMFYA axial psoriatic arthritis primary endpoint achievement (2026-09-25) (company announcements — may reflect promotional framing).
Nature Biotechnology updates from 2026-09-21 through 2026-09-27 including a new Brief Communication on photolabile oligonucleotides for spatially resolved single-cell transcriptomics (2026-09-25), and ongoing coverage of gene editing using large insertions, proteomic aging clocks in clinical trials, and AI-enhanced virtual screening.
IFPMA press releases and statements from 2026-09-23 through 2026-09-26 covering the press release on pandemic preparedness innovation (2026-09-23), statement at the UN High-Level Meeting on PPPR (2026-09-25), and consideration of the Political Declaration on PPPR statement (2026-09-26) (company announcements — may reflect promotional framing).
STAT News article reporting FDA approval of Fayuvi, a gene therapy developed by Ultragenyx for Sanfilippo syndrome type A, the first drug specifically approved to treat the condition, sometimes known as childhood Alzheimer's.
STAT News article reporting reinvigorated interest from drugmakers and biotech VCs in osteoporosis treatments, driven by new FDA guidance and frustration with existing therapies, with Eli Lilly recruiting scientists and venture capitalists making bone health a priority.
IFPMA statement on 2026-09-26 at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response, urging governments to adopt policies enabling discovery and development of life-saving products and strengthen delivery systems (company announcement — may reflect promotional framing).
Pharma & Biotechを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める